Yan Zhu^1,#, Bin Guan^1,#, Wencai Guan¹, Jihong Zhang¹, Shiyu Wang¹, Jimin Shi¹, Wei Fan¹, Qi Lu^2,3, Lingyun Zhang^4,5,*, Guoxiong Xu^1,2,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.075241 - 22 April 2026

Abstract Background: Ovarian cancer poses the greatest threat to survival among gynecologic cancers in women. Long non-coding RNAs (lncRNAs) have emerged as critical regulators in oncogenesis. The current study aimed to elucidate the function and regulatory mechanism of lncRNA KRT7-AS in ovarian cancer. Methods: The clinical significance of KRT7-AS was evaluated through bioinformatics analysis of data from public repositories. KRT7-AS expression was examined by RT-qPCR and fluorescence in situ hybridization. The function analyses were conducted using assays for cell proliferation, migration, invasion, wound healing, and colony formation. Assessment of cell cycle and apoptosis was performed using flow… More >

Yin-Lun Chang^1,2, Hao-Lun Luo¹, Jei-Ming Peng^3,*, Chang-Chun Hsiao^2,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.070837 - 23 March 2026

Abstract Background: Upper tract urothelial carcinoma (UTUC) is an aggressive malignancy with high recurrence rates. Lymphovascular invasion (LVI) predicts a poor prognosis, yet its molecular drivers remain unclear. BOC cell adhesion-associated, oncogene-regulated (BOC, also known as Brother of CDO [Cell adhesion molecule-Related/Down-regulated by Oncogenes]), a hedgehog-related cell surface receptor, may serve as a biomarker for tumor progression and chemotherapy response. The study aimed to investigate the role of BOC in UTUC and its potential to predict LVI and chemotherapy response. Methods: Sequencing (RNA-seq) of 10 stage III UTUC, treatment-naïve, fresh tissue samples identified BOC as a… More >

Daniel Burg¹, Aryeh Babkoff¹, Omer Or², Noam Olshinka², Jonathan Abraham Demma³, Mohamad Adila^1,3, Marc Wygoda⁴, Philip Blumenfeld⁴, Judith Diment⁵, Masha Galiner⁶, Yusef Azraq⁶, Daniela Katz^1,7, Petachia Reissman⁸, Sadie Ostrowicki⁹, Gabriella Sebbag¹⁰, Narmine Elkhateeb^1,11, Anat Hershko Moshe^1,11, Dania Jaber^1,11, Adi Hollander^1,11, Limor Rubin^1,11, Aviad Zick^1,12,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.070233 - 23 March 2026

Abstract Background: —Synovial sarcoma is a rare soft tissue sarcoma. Treatment of synovial sarcoma includes surgery, radiation, pazopanib, and chemotherapy. Targeted therapies, such as B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitors, are emerging as a potential treatment option. We describe the sixth case of a BRAF^V600E synovial sarcoma, the first extra-thoracic case. This case is the first to show a complete pathological response to BRAF & mitogen-activated protein kinase kinase (MEK) inhibitors. Case description: —We treated a 22-year-old male with a left groin BRAF^V600E synovial sarcoma with doxorubicin, Ifosphamide & Sodium 2-Mercaptoethanesulfonate. When we identified BRAF^V600E in the tumor,… More >

Yuanxin Miao^1,2, Fengyun Hao^3,*, Sae Hwi Ki^1,4,*

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2025.071034 - 24 February 2026

Abstract Objectives: The eukaryotic initiation factor 4F (eIF4F) translation initiation complex inhibitors (eIF4Fi) were recently found to hyperactivate extracellular signal-regulated kinases 1/2 (ERK1/2) signals, which contribute to acquired resistance to BRAF (B-Raf proto-oncogene, serine/threonine kinase) inhibitors in melanoma. This present study aims to elucidate how to overcome the resistance of the eIF4Fi in BRAF^V600E mutant melanoma cells and explore the underlying mechanisms. Methods: Melanoma A375 (vemurafenib [VEM]-sensitive) and A375R (VEM-resistant) cells were exposed to eIF4Fi RocA at varying doses and durations in vitro. We investigated the impact of RocA on the activity of ERK1/2, AKT serine/threonine kinase 1… More >

Katerina Ondraskova^1,2, Matous Cwik³, Ondrej Horky⁴, Jitka Berkovcova⁴, Jitka Holcakova¹, Martin Bartosik¹, Tomas Kazda⁵, Klara Mrazova^1,6, Michal Uher⁷, Igor Kiss³, Roman Hrstka^1,3,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.070116 - 19 January 2026

Abstract Objectives: Cancer treatment relies heavily on accurate diagnosis and effective monitoring of the disease. These processes often involve invasive procedures, such as colonoscopy, to detect malignant tissues, followed by molecular analyses to determine relevant biomarkers. This study aimed to evaluate the clinical performance of droplet digital PCR (ddPCR) for detecting Kirsten Rat Sarcoma Viral Proto-Oncogene (KRAS), Neuroblastoma RAS Viral Oncogene Homolog (NRAS), and B-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutations in circulating tumor DNA (ctDNA) from colorectal cancer patients using liquid biopsy. Methods: ctDNA was isolated from colorectal cancer (CRC) patients (n = 110) and analyzed for KRAS, BRAF,… More >

KEFAN LIU¹, XIAOSONG WANG¹, XIN YANG¹, BOWEN SHI¹, LEI XING^2,*, JUNXIA CHEN^1,*

Oncology Research, Vol.33, No.7, pp. 1709-1722, 2025, DOI:10.32604/or.2025.061721 - 26 June 2025

Abstract Background: Accumulating studies have shown the important role of circular RNAs (circRNAs) in the oncogenesis and metastasis of various cancers. We previously reported that circACTN4 could bind with FUBP1 to promote tumorigenesis and the development of breast cancer (BC) by increasing the expression of MYC. However, its exact molecular mechanism and biological function have not been fully elucidated. Methods: Here, Circular RNA microarray analysis was conducted in 3 pairs of BC and paracancerous tissues. The expression of circACTN4 in BC cells and tissues was detected via reverse transcription‒quantitative PCR (RT‒qPCR). Cell Counting Kit-8 (CCK-8), 5-ethynyl-2-deoxyuridine… More > Graphic Abstract

Gege Liu^#, Houfang Zhang^#, Yunhui Peng^*

BIOCELL, Vol.49, No.4, pp. 519-538, 2025, DOI:10.32604/biocell.2025.061470 - 30 April 2025

Abstract Nucleosomes play a vital role in chromatin organization and gene regulation, acting as key hubs that interact with various chromatin-associated factors through diverse binding mechanisms. Recent research has highlighted the prevalence of mutations in linker histones across different types of cancer, emphasizing their critical involvement in cancer progression. These cancer-associated mutations in linker histones have been shown to disrupt nucleosome stacking and the formation of higher-order chromatin structures, which in turn significantly affect epigenetic regulatory processes. In this review, we provide a comprehensive analysis of how cancer-associated linker histone mutations alter their physicochemical properties, influencing More >

XIAOBI HUANG¹, CHUNYUAN CHEN², YONGYANG CHEN¹, HONGLIAN ZHOU¹, YONGHUA CHEN¹, ZHONG HUANG¹, YULIU XIE¹, BAIYANG LIU¹, YUDONG GUO¹, ZHIXIONG YANG¹, GUANGHUA CHEN³, WENMEI SU^1,4

Oncology Research, Vol.33, No.5, pp. 1249-1250, 2025, DOI:10.32604/or.2024.061822 - 18 April 2025

Abstract This article has no abstract. More >

AMJAD YOUSUF¹, NAJEEB ULLAH KHAN^2,*

Oncology Research, Vol.33, No.4, pp. 851-861, 2025, DOI:10.32604/or.2025.058956 - 19 March 2025

Abstract Breast cancer is a significant global concern, with limited effective treatment options. Therefore, therapies with high efficacy and low complications, unlike the existing chemotherapies, are urgently required. To address this issue, advances have been made in therapies targeting molecular pathways related to the murine double minute 2 proto-oncogene (MDM2)-tumor proteinp53 (TP53) interaction. This review aims to investigate the efficacy of MDM2 inhibition in restoring TP53 activity in breast cancer cells, as evidenced by clinical studies, reviews, and trials. TP53 is a tumor suppressor and MDM2 facilitates proteasomal degradation of TP53. MDM2 and TP53 activity More > Graphic Abstract

GUANGXIAN YOU¹, QIAO YANG², XIN LI², LILI CHEN^2,*

Oncology Research, Vol.33, No.4, pp. 905-917, 2025, DOI:10.32604/or.2024.052089 - 19 March 2025

Abstract Background: Lung cancer remains a major factor causing cancer-associated mortality globally. While there have been advancements in treatment options, advanced lung cancer patients still have poor outcomes. This study aims to investigate the potential role of Transmembrane protein 33 (TMEM33) in the development of lung adenocarcinoma. Methods: We leveraged The Cancer Genome Atlas (TCGA) database to analyze the connection between TMEM33 expression to the prognosis of lung adenocarcinoma (LUAD). Cell proliferation, invasiveness, and sphere formation were analyzed by various experiments. The association of miR-214-3p with TMEM33 was explored using luciferase reporter assay, immunoblotting, and real-time… More >